Roche's CEO Warns Russia-Ukraine War Causing Problems For MS Trials

 

• The development of Roche Holdings AG's 
  RHHBY
   multiple sclerosis candidate fenebrutinib is negatively impacted by Russia's ongoing invasion of Ukraine.
• Reuters reported that between 20% and 30% of clinical trial participants for the phase 3 drug are in the two countries.
• "Both Ukraine and Russia historically have been very important contributors to clinical trials for patients with neurological disorders such as multiple sclerosis," Roche (RHHBY) CEO Bill Anderson said.
• As a result, Roche (RHHBY) is recruiting for sites in countries it already has ongoing trials and is opening sites in new countries.
• For a phase 3b trial testing a higher dose of Ocrevus and studies for experimental oral BTK inhibitor fenebrutinib for MS, Roche had to open additional sites in other countries, Anderson said.
• While the war has massively disrupted trials in Ukraine, no more new trial participants will be recruited in Russia as part of Roche's response to Moscow's invasion.

https://www.benzinga.com/general/biotech/22/04/26795150/roches-ceo-warns-russia-ukraine-war-causing-problems-for-multiple-sclerosis-trials